Form 4: Celularity Director Vincent LeVien Granted Stock Options

Celularity Inc. director Vincent LeVien was granted 186,336 stock options with an exercise price of $1.92, vesting over three years starting June 5, 2026.

Summary

• Vincent LeVien, a Director of Celularity Inc. (CELU), was granted 186,336 stock options.
• The options have an exercise price of $1.92 per share.
• The options are set to expire on June 5, 2035.
• A portion of the options, specifically 62,112, will vest annually over three years, with the vesting period commencing on June 5, 2026.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice for aligning management incentives with shareholder interests. It is a routine compensation event and does not indicate any immediate positive or negative operational or financial news for the company.

Positives

• The grant of stock options to a director aligns their financial interests with those of shareholders, incentivizing long-term performance and potential share price appreciation.
• The options have a 10-year expiration period, providing a substantial window for potential value realization.

Negatives

• The vesting schedule extends over three years, delaying the full beneficial ownership and potential exercise of all options.

Future Outlook

The filing indicates a future vesting schedule for the granted stock options, with 62,112 options vesting annually over three years starting June 5, 2026. The options themselves expire on June 5, 2035.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Celularity Inc., to attract and retain talent and align executive incentives with long-term shareholder value creation. This practice is standard across many growth-oriented sectors where future potential is a key driver of valuation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice in publicly traded companies, particularly prevalent in the biotechnology and cell therapy sectors.
• Companies like Celularity Inc., which operate in high-growth, research-intensive fields, frequently utilize equity-based incentives to attract and retain key talent and align their interests with long-term shareholder value.
• While specific comparable grants are not detailed, similar compensation structures are common among peers such as Fate Therapeutics, Inc. or Allogene Therapeutics, Inc., reflecting an industry-wide approach to executive and director remuneration.

Related Party Transactions

• This filing details a stock option grant to a director, which is a common form of related party transaction (compensation to an insider).

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term share price appreciation, potentially benefiting shareholders if the company performs well. It also represents a potential future dilution if options are exercised, though this is typically factored into equity compensation plans.

Next Steps

• The vesting of 62,112 options annually over three years, beginning on June 5, 2026.
• Potential exercise of vested options by Vincent LeVien before the expiration date of June 5, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director and does not contain information that would fundamentally alter the investment thesis for Celularity Inc. It is a standard compensation practice aimed at aligning interests, and as such, it does not provide new insights into the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Celularity Inc., CELU, Stock Options, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership, Equity Grant, Vesting